Finasteride Use and Safety Considerations

Introduction to Finasteride Therapy

• The American College of Physicians recommends finasteride as a treatment option for benign prostatic hyperplasia (BPH) with prostate enlargement, as it reduces overall prostate cancer incidence by approximately 25% over 7 years 1, 2
• The American Urological Association suggests that finasteride is most effective in men with demonstrable prostatic enlargement (>30cc) 5, 4, 3

Prostate Cancer Risk Profile

• The National Comprehensive Cancer Network notes that finasteride reduces overall prostate cancer incidence, but there is an increased detection of high-grade prostate cancer (Gleason 8-10) 1, 2
• The European Association of Urology recommends that men aged 55 and older with normal digital rectal examination and PSA ≤3.0 ng/mL should be monitored for increased high-grade cancer risk 1, 2

Critical Monitoring Requirements

• The American College of Physicians recommends adjusting PSA interpretation, as finasteride reduces PSA by approximately 50% after 6 months of therapy, and doubling the measured PSA value after 1 year of therapy for accurate prostate cancer screening 3, 4
• The American Urological Association suggests performing digital rectal examination to assess for prostate nodularity, asymmetry, or concerning findings 3

Common Side Effects

• The National Institute of Health reports that finasteride is associated with sexual dysfunction, including decreased libido (6.4% first year, 2.6% years 2-4), ejaculatory dysfunction (3.7% first year, 1.5% years 2-4), and erectile dysfunction (4-15%) 3, 6, 1, 7
• The European Association of Urology notes that finasteride may cause breast changes, including gynecomastia, breast tenderness, and breast enlargement 3

Clinical Algorithm for Finasteride Use

• The American Urological Association recommends confirming appropriate indication, baseline assessment, and counseling on prostate cancer risk and sexual side effects before initiating finasteride therapy 5, 4, 3, 1, 2, 7
• The National Comprehensive Cancer Network suggests establishing a monitoring plan, including periodic PSA checks and digital rectal exams, to assess response to finasteride therapy 4, 3